| pubmed-article:14510948 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14510948 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:14510948 | lifeskim:mentions | umls-concept:C0231335 | lld:lifeskim |
| pubmed-article:14510948 | lifeskim:mentions | umls-concept:C0023449 | lld:lifeskim |
| pubmed-article:14510948 | lifeskim:mentions | umls-concept:C0948441 | lld:lifeskim |
| pubmed-article:14510948 | lifeskim:mentions | umls-concept:C0677908 | lld:lifeskim |
| pubmed-article:14510948 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:14510948 | pubmed:dateCreated | 2003-9-26 | lld:pubmed |
| pubmed-article:14510948 | pubmed:abstractText | The case records of 99 consecutive children with acute lymphoblastic leukaemia who received either 6-thioguanine (6-TG) or 6-mercaptopurine (6-MP) as maintenance therapy for at least 1 year were reviewed for hepatic veno-occlusive disease (VOD). Overall, 12% of those on 6-TG developed VOD (all boys). Isolated persistent thrombocytopenia appeared to be the earliest indicator of incipient VOD. Multivariate analysis identified male sex and 6-TG as risk factors. In all cases, VOD was mild and reversible on withdrawing 6-TG or replacing it with 6-MP. The data implicate a sex-linked polymorphic variation in xenobiotic pathways of thiopurine metabolism in the pathogenesis of VOD. | lld:pubmed |
| pubmed-article:14510948 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14510948 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14510948 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14510948 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14510948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14510948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14510948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14510948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14510948 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14510948 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:14510948 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:14510948 | pubmed:author | pubmed-author:SahaVaskarV | lld:pubmed |
| pubmed-article:14510948 | pubmed:author | pubmed-author:CoenPietroP | lld:pubmed |
| pubmed-article:14510948 | pubmed:author | pubmed-author:LilleymanJohn... | lld:pubmed |
| pubmed-article:14510948 | pubmed:author | pubmed-author:LennardLynneL | lld:pubmed |
| pubmed-article:14510948 | pubmed:author | pubmed-author:StonehamSaraS | lld:pubmed |
| pubmed-article:14510948 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14510948 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:14510948 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14510948 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14510948 | pubmed:pagination | 100-2 | lld:pubmed |
| pubmed-article:14510948 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:meshHeading | pubmed-meshheading:14510948... | lld:pubmed |
| pubmed-article:14510948 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14510948 | pubmed:articleTitle | Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. | lld:pubmed |
| pubmed-article:14510948 | pubmed:affiliation | Cancer Research UK, Children's Cancer Group, Bart's and The London, Queen Mary School of Medicine and Dentistry, London, UK. sara.stoneham@cancer.org.uk | lld:pubmed |
| pubmed-article:14510948 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14510948 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:14510948 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14510948 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14510948 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14510948 | lld:pubmed |
